

B 4. (amended) [Bacterium according to claims 1-3] The bacterium according to claim 1, wherein said bacterium is selected from the group consisting of *S. typhimurium*, *enteritidis*, *choleraesuis*, *dublin*, *typhi*, *abortus-ovi*, *abortus-equu*, *paratyphi A and B*, *derby*, *hadar*, *heidelberg*, *agona* and *arizonae*.

5. (amended) [Bacterium according to claim 1-4] The bacterium according to claim 1, wherein said bacterium further carries a heterologous gene[, said heterologous gene preferably being inserted in the flagellin gene].

A¹ *X* *B¹* *B²* 6. (amended) [Bacterium] The bacterium according to claim 1, [characterised in that it belongs to a] having the same immunological characteristics as the strain [of which an example] that has been deposited with the Centraalbureau voor Schimmelcultures under accession-number CBS 108955.

SUP 7. (amended) Vaccine for the protection of animals against Salmonellosis, [characterised in that the vaccine comprises bacterium as defined in claims 1-6] comprising an immunogenically effective amount of bacteria as defined in claim 1 or antigenic material thereof and a pharmaceutically acceptable carrier.

8. (amended) [Vaccine] The vaccine according to claim 7, [characterised in that said bacteria are] wherein the bacteria is in a live attenuated form.

9. (amended) [Vaccine] The vaccine according to claim 7, [characterised in that said] wherein the bacteria are inactivated.

10. (amended) The vaccine according to [claims 7-9, characterised in that it comprises] claim 7 comprising an adjuvant.